文献速递姑息放疗与转移瘤乳腺癌放疗胸部肿瘤放疗

寡转移灶定向SBRT后短期生活质量:ESTRO与EORTC OligoCare队列结果

Short-term quality of life after metastases-directed SBRT: Results of the ESTRO & EORTC OligoCare cohort.
PubMed 文献 · Radiother Oncol · 2026-06-18

OligoCare前瞻性队列纳入2041例寡转移乳腺癌、结直肠癌、非小细胞肺癌和前列腺癌患者,1033例完成基线HRQoL问卷,450例有随访数据,中位随访2.7个月。基线中位GHS为75,随访时均值稳定在71(SD 19),23%患者HRQoL恶化、15%改善,未发现HRQoL变化与临床变量的显著关联。

要点

  • 寡转移患者SBRT后短期整体HRQoL保持稳定,多数患者未出现下降。
  • 基线GHS较高与前列腺癌及良好体能状态相关(p < 0.0001)。
  • 23%患者随访时HRQoL恶化、15%改善,变化与临床变量无显著关联。

核心结论

  • 早期结果表明,寡转移疾病SBRT在多数患者中维持整体HRQoL,支持其在不损害患者报告结局的前提下用于多模式治疗。

研究设计与样本

  • OligoCare是E2-RADIatE注册平台内的实用性前瞻性队列研究,纳入接受SBRT的寡转移乳腺癌、结直肠癌、非小细胞肺癌和前列腺癌患者。
  • 可选HRQoL子研究在基线和SBRT后6个月内评估患者报告结局,共2041例患者中1033例(50.6%)完成基线问卷、450例(22%)有随访数据。

主要发现

  • 随访HRQoL评估的中位时间为2.7个月(范围0.5-6.1)。
  • 基线中位GHS为75,随访时平均GHS保持稳定为71(SD 19)。
  • 有随访数据的患者中,23%报告HRQoL恶化、15%改善。
  • 未发现HRQoL变化与临床变量之间存在显著关联。

关键数值与推荐

  • 临床意义变化定义为最小临床重要差异(MCID)≥ 10分。
  • 基线GHS较高与前列腺癌及良好体能状态相关(p < 0.0001)。

临床怎么用

  • 对于寡转移乳腺癌、结直肠癌、非小细胞肺癌和前列腺癌患者,SBRT后短期整体HRQoL多可维持,可据此与患者沟通治疗对生活质量的有限影响。

局限性

  • 仅50.6%患者完成基线HRQoL问卷、22%有随访数据,存在选择偏倚可能。
  • 随访时间短,中位仅2.7个月(范围0.5-6.1),无法反映长期HRQoL变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Metastasis-directed stereotactic body radiotherapy (SBRT), in combination with systemic therapy, is increasingly used in patients with oligometastatic disease (OMD), supported by international guidelines. However, real-world data on health-related quality of life (HRQoL) following SBRT remain limited. This study aimed to describe baseline HRQoL, evaluate changes over time, and identify clinical factors associated with HRQoL and its evolution. MATERIALS AND METHODS: OligoCare is a pragmatic, prospective cohort study within the E2-RADIatE registry, including patients with oligometastatic breast, colorectal, non-small cell lung cancer (NSCLC), and prostate cancer treated with SBRT. An optional HRQoL sub-study assesses patient-reported outcomes at baseline and within 6 months post-SBRT. Analyses included descriptive assessment of baseline HRQoL, multivariable regression to identify factors associated with baseline global health status (GHS), and longitudinal evaluation of HRQoL changes. Clinically meaningful changes were defined using a minimal clinically important difference (MCID) of ≥ 10 points. RESULTS: Of 2,041 patients, 1,033 (50.6%) completed baseline HRQoL questionnaires and 450 (22%) had follow-up data. The median time to follow-up HRQoL assessment was 2.7 months (range 0.5-6.1). Median baseline GHS was 75. Higher baseline GHS was associated with prostate cancer and good performance status (p < 0.0001). At follow-up, mean GHS remained stable (71, SD 19). Among patients with follow-up data, 23% reported worsened HRQoL, 15% improved. No significant associations were found between HRQoL changes and clinical variables. CONCLUSION: Early findings support that SBRT for OMD maintains overall HRQoL in most patients, reinforcing its role in multimodal treatment without compromising patient-reported outcomes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Greto D, Van Hemelrijck M, Oppong F, et al. Short-term quality of life after metastases-directed SBRT: Results of the ESTRO & EORTC OligoCare cohort. Radiother Oncol. 2026. PMID: 42314835. doi:10.1016/j.radonc.2026.111645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。